HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
PTPRS
protein tyrosine phosphatase receptor type S
Chromosome 19 · 19p13.3
NCBI Gene: 5802Ensembl: ENSG00000105426.20HGNC: HGNC:9681UniProt: Q13332
87PubMed Papers
20Diseases
0Drugs
1Pathogenic Variants
FUNCTIONAL ROLE
Receptor
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
negative regulation of interferon-beta productionnegative regulation of toll-like receptor 9 signaling pathwayprotein dephosphorylationprotein bindingatrial fibrillationAlzheimer diseaseneurodegenerative diseaseleukoplakia of penis
✦AI Summary

PTPRS (protein tyrosine phosphatase receptor type S) is a transmembrane cell surface receptor that functions as both an extracellular glycosaminoglycan-binding protein and an intracellular tyrosine phosphatase. PTPRS binds chondroitin sulfate and heparan sulfate proteoglycans with opposing effects on neuronal outgrowth; it inhibits neurite extension via chondroitin sulfate interactions while promoting growth through heparan sulfate engagement 1. As a phosphatase, PTPRS dephosphorylates neurotrophic receptor kinases and suppresses downstream Akt and MAP kinase signaling 2. It also functions as an inhibitory immune receptor on plasmacytoid dendritic cells, downregulating TLR9-mediated interferon and TNF production 3. PTPRS is required for normal pituitary and olfactory bulb development. Clinically, PTPRS dysfunction associates with multiple diseases. A neuroprotective PTPRS variant correlates with delayed Alzheimer's disease onset, particularly in males, through preservation of synaptic markers 4. Loss of PTPRS expression promotes epithelial-mesenchymal transition in neurofibromas via EGFR activation 5 and enhances glioblastoma metastatic potential and temozolomide resistance through MAPK-MEK-ERK signaling 6. Conversely, PTPRS deletion prevents intestinal inflammation by enhancing interferon responses in dendritic cells 3. These findings identify PTPRS as a context-dependent tumor suppressor with therapeutic potential through receptor activation 7.

Sources cited
1
PTPRS binds chondroitin sulfate and heparan sulfate proteoglycans with opposite effects on oligomerization and neurite outgrowth
PMID: 21454754
2
PTPRS functions as a tyrosine phosphatase
PMID: 8524829
3
PTPRS is an inhibitory receptor on plasmacytoid dendritic cells that downregulates TLR9-mediated interferon and TNF production
PMID: 26231120
4
PTPRS variant C shows neuroprotection against early Tau pathology and synaptic degeneration in Alzheimer's disease, with a 10-month delay in disease onset in male carriers
PMID: 38926456
5
Reduced PTPRS expression promotes epithelial-mesenchymal transition in NF1-derived plexiform neurofibromas through EGFR-mediated pathways
PMID: 39094827
6
Loss of PTPRS in glioblastoma enhances metastatic capability and temozolomide resistance through MAPK-MEK-ERK signaling
PMID: 38517048
7
PTPRS activity can be modulated by antibodies targeting the fibronectin-type III domain to disrupt HSPG oligomerization, with therapeutic potential in rheumatoid arthritis
PMID: 40651610
Disease Associationsⓘ20
atrial fibrillationOpen Targets
0.45Moderate
Alzheimer diseaseOpen Targets
0.37Weak
neurodegenerative diseaseOpen Targets
0.36Weak
Conductive hearing impairmentOpen Targets
0.35Weak
leukoplakia of penisOpen Targets
0.35Weak
multiple sclerosisOpen Targets
0.32Weak
lysosomal storage diseaseOpen Targets
0.32Weak
Parkinson diseaseOpen Targets
0.32Weak
placental retentionOpen Targets
0.31Weak
Abnormal pupillary functionOpen Targets
0.31Weak
diabetes mellitusOpen Targets
0.27Weak
liver diseaseOpen Targets
0.27Weak
NK-cell enteropathyOpen Targets
0.26Weak
placenta praeviaOpen Targets
0.26Weak
AlkalosisOpen Targets
0.24Weak
chondromalaciaOpen Targets
0.24Weak
HypercholesterolemiaOpen Targets
0.18Weak
sign or symptomOpen Targets
0.16Weak
Abruptio PlacentaeOpen Targets
0.15Weak
Hearing impairmentOpen Targets
0.14Weak
Pathogenic Variants1
NM_002850.4(PTPRS):c.4756G>A (p.Val1586Met)Likely pathogenic
NK-cell enteropathy
☆☆☆☆2019→ Residue 1586
View on ClinVar ↗
Related Genes
NTRK3Protein interaction100%RTN4Protein interaction99%PPFIA1Protein interaction99%IL1RAPProtein interaction95%SLITRK1Protein interaction94%PPFIBP1Protein interaction92%
Tissue Expression6 tissues
Ovary
100%
Brain
63%
Lung
49%
Heart
32%
Bone Marrow
24%
Liver
21%
Gene Interaction Network
Click a node to explore
PTPRSNTRK3RTN4PPFIA1IL1RAPSLITRK1PPFIBP1
PROTEIN STRUCTURE
Preparing viewer…
PDB2FH7 · 2.00 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.38Moderately Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.31 [0.25–0.38]
RankingsWhere PTPRS stands among ~20K protein-coding genes
  • #5,508of 20,598
    Most Researched87
  • #4,936of 5,498
    Most Pathogenic Variants1
  • #1,807of 17,882
    Most Constrained (LOEUF)0.38 · top quartile
Genes detectedPTPRS
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
PTPRS is a novel marker for early Tau pathology and synaptic integrity in Alzheimer's disease.
PMID: 38926456
Sci Rep · 2024
1.00
2
Apical junction complex proteins and ulcerative colitis: a focus on the PTPRS gene.
PMID: 18598228
Expert Rev Mol Diagn · 2008
0.90
3
Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells.
PMID: 26231120
Immunity · 2015
0.80
4
Reduced PTPRS expression promotes epithelial-mesenchymal transition of Schwann cells in NF1-related plexiform neurofibromas.
PMID: 39094827
Cancer Lett · 2024
0.70
5
Modulation of the PTPRS proteoglycan switch by antibodies binding to the membrane-proximal fibronectin-type III domain.
PMID: 40651610
J Biol Chem · 2025
0.60